266 related articles for article (PubMed ID: 19862481)
1. Intense accumulation of 18F-FDG, not enhancement on MRI, helps to guide the surgical biopsy accurately in soft tissue tumors.
Park JH; Park EK; Kang CH; Kim CH; Choe JG; Noh W
Ann Nucl Med; 2009 Dec; 23(10):887-9. PubMed ID: 19862481
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
3. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours?
Hain SF; O'Doherty MJ; Bingham J; Chinyama C; Smith MA
Nucl Med Commun; 2003 Nov; 24(11):1139-43. PubMed ID: 14569167
[TBL] [Abstract][Full Text] [Related]
4. Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma.
Eary JF; Conrad EU; Bruckner JD; Folpe A; Hunt KJ; Mankoff DA; Howlett AT
Clin Cancer Res; 1998 May; 4(5):1215-20. PubMed ID: 9607579
[TBL] [Abstract][Full Text] [Related]
5. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial.
Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495
[TBL] [Abstract][Full Text] [Related]
6. Utility of positron emission tomography in sarcomas.
Schuetze SM
Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
[TBL] [Abstract][Full Text] [Related]
7. Surgical considerations when reporting MRI studies of soft tissue sarcoma of the limbs.
De La Hoz Polo M; Dick E; Bhumbra R; Pollock R; Sandhu R; Saifuddin A
Skeletal Radiol; 2017 Dec; 46(12):1667-1678. PubMed ID: 28884363
[TBL] [Abstract][Full Text] [Related]
8. Contemporary imaging in sarcoma.
Landa J; Schwartz LH
Oncologist; 2009 Oct; 14(10):1021-38. PubMed ID: 19789392
[TBL] [Abstract][Full Text] [Related]
9. PROLONGED FEVER WITHOUT OBVIOUS ETIOLOGY FINALLY DIAGNOSED AS HIGH-GRADE SOFT TISSUE SARCOMA.
Doroftei NA; de Visscher N
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):100-4. PubMed ID: 27125079
[TBL] [Abstract][Full Text] [Related]
10. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET.
Benz MR; Dry SM; Eilber FC; Allen-Auerbach MS; Tap WD; Elashoff D; Phelps ME; Czernin J
J Nucl Med; 2010 Aug; 51(8):1174-81. PubMed ID: 20660389
[TBL] [Abstract][Full Text] [Related]
11. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
12. Small, superficial, indeterminate soft-tissue lesions as suspected sarcomas: is primary excision biopsy suitable?
Khoo M; Pressney I; Hargunani R; Saifuddin A
Skeletal Radiol; 2017 Jul; 46(7):919-924. PubMed ID: 28361352
[TBL] [Abstract][Full Text] [Related]
13. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Evilevitch V; Weber WA; Tap WD; Allen-Auerbach M; Chow K; Nelson SD; Eilber FR; Eckardt JJ; Elashoff RM; Phelps ME; Czernin J; Eilber FC
Clin Cancer Res; 2008 Feb; 14(3):715-20. PubMed ID: 18245531
[TBL] [Abstract][Full Text] [Related]
14. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
15. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma.
Vernon CB; Eary JF; Rubin BP; Conrad EU; Schuetze S
Skeletal Radiol; 2003 Mar; 32(3):139-42. PubMed ID: 12605277
[TBL] [Abstract][Full Text] [Related]
16. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
18. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
[TBL] [Abstract][Full Text] [Related]
19. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
[TBL] [Abstract][Full Text] [Related]
20. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
